Acetaminophen/Paracetamol

Phase 3Small molecule

Acetaminophen/Paracetamol is one of 130 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Pemphigus VulgarisActive, not recruiting

Lupus NephritisActive, not recruiting

Vascular DiseaseActive, not recruiting

Systemic Lupus ErythematosusPhase 3

Active, not recruiting

Pemphigus VulgarisPhase 3

Active, not recruiting

Lupus NephritisPhase 2

Active, not recruiting

Vascular DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

9 2

Medrol

Pfizer

Phase 3

5 3

Olumiant

Eli Lilly

Phase 3

4 4

Stelara

Johnson & Johnson

Phase 3

3 5

Ocrevus

Roche

Phase 3

2 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

11 7

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 8

Depo-Provera

Eli Lilly

Phase 3

—9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 10

Imuran

LLegacy Health System

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Systemic Lupus Erythematosus

NCT04963296

Q2 2030

Phase 2Recruiting

Lupus Nephritis

NCT05039619

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04963296·303 enrolled

Pemphigus Vulgaris1 trial

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

Terminated· GSK logo

GSK·Phase 3·NCT02613910·1 enrolled

Vascular Disease1 trial

Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00662818·165 enrolled

Lupus Nephritis1 trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)

Recruiting· Roche logo

Roche·Phase 2·NCT05039619·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Acetaminophen/Paracetamol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acetaminophen/Paracetamol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acetaminophen/Paracetamol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Acetaminophen/Paracetamol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2030

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

Pemphigus Vulgaris1 trial

Vascular Disease1 trial

Lupus Nephritis1 trial

References

Drug Info

Quick Facts

Related News